Intracerebral Bleeding in Patients on Antithrombotic Agents

Abstract

Patients treated with oral anticoagulants (OAC) carry a 7- to 10-fold higher risk of intracerebral hemorrhage (ICH) than patients without OAC. ICH related to oral anticoagulation (OAC-ICH) is a particularly severe form of stroke. The overall incidence of OAC-ICH ranges between 2 and 9 per 100,000 population/year and is expected to increase as the number of patients treated with OAC rises. Besides common risk factors of ICH such as age and hypertension, the intensity of anticoagulation, previous ischemic stroke, and the presence of cerebral vasculopathies (e.g., amyloid angiopathy, subcortical hypertensive arteriopathy) are associated with a greater risk of OAC-ICH. Mortality rates in OAC-ICH of 52 to 67% considerably exceed those of ICH in nonanticoagulated patients. Factors that mediate worse outcome in OAC-ICH are more frequent and prolonged secondary hematoma enlargement and intraventricular hemorrhage, The current concept of emergency treatment in OAC-ICH is rapid restoration of effective coagulation using hemostatic factors such as prothrombin complex concentrate, fresh frozen plasma, factor IX concentrates, and recombinant factor VIIa in addition to vitamin K. Emergency management of ICH under treatment with the new direct OAC is a major challenge. In the absence of specific antidotes, prothrombin concentrates are recommended mainly on the basis of preclinical data.

Keywords

intracerebral hemorrhage - warfarin - oral anticoagulation

• References

• 1 Morgenstern LB, Hemphill JC, Anderson C , et al. Guideline for Healthcare Professionals from the American Heart AHA/ASA Guideline Intracerebral Hemorrhage A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-2129
• 2 Steiner T, Kaste M, Forsting M , et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracreebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006; 22 (4) 294-316
• 3 Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40 (2) 394-399
• 4 Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry 2005; 76 (11) 1534-1538
• 5 Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24 (7) 987-993
• 6 Mendelow AD, Gregson BA, Fernandes HM , et al; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365 (9457) 387-397
• 7 Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34 (8) 2060-2065
• 8 O'Donnell MJ, Xavier D, Liu L , et al; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376 (9735) 112-123
• 9 Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55 (7) 947-951
• 10 Charidimou A, Baron JC, Werring DJ. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. Int J Stroke 2013; 8 (2) 105-108
• 11 Charidimou A, Meegahage R, Fox Z , et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry 2013; 84 (6) 624-629
• 12 Hirsh J, Guyatt G, Albers GW , et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6) Suppl 110S-112S
• 13 Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Cassiopea Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379 (9811) 123-129
• 14 Kearon C, Gent M, Hirsh J , et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907
• 15 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
• 16 Rost S, Fregin A, Ivaskevicius V , et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427 (6974) 537-541
• 17 Li T, Chang C-Y, Jin D-Y, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427 (6974) 541-544
• 18 Hirsh J, Anand SS, Halperin JL, Fuster V. American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103 (24) 2994-3018
• 19 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
• 20 Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123 (7) 638-645 , e4
• 21 Taggar JS, Lip GYH. Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. Curr Med Res Opin 2008; 24 (5) 1455-1458
• 22 Schwarz UI, Ritchie MD, Bradford Y , et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358 (10) 999-1008
• 23 Arnold M-L, Grond-Ginsbach C, Kloss M , et al. Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients. Cerebrovasc Dis 2009; 28 (5) 468-471
• 24 Oldenburg J, Marinova M, Müller-Reible C, Watzka M. The vitamin K cycle. Vitam Horm 2008; 78: 35-62
• 25 Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006; 37 (1) 256-262
• 26 Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3, Suppl) 287S-310S
• 27 Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care 2007; 25 (2) 123-128
• 28 Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30 (10) 1885-1889
• 29 Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103 (1) 62-70
• 30 Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl. 02) S5-S12
• 31 Hohnloser SH, Crijns HJ, van Eickels M , et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360 (7) 668-678
• 32 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 33 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147 (9) 1561-1564
• 34 Heeringa J, van der Kuip DAM, Hofman A , et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27 (8) 949-953
• 35 Go AS, Hylek EM, Phillips KA , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18) 2370-2375
• 36 Flaherty ML, Kissela B, Woo D , et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68 (2) 116-121
• 37 Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21 (5) 726-730
• 38 Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63 (6) 1059-1064
• 39 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164 (8) 880-884
• 40 Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63 (6) 1059-1064
• 41 Flaherty ML, Kissela B, Woo D , et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68 (2) 116-121
• 42 Lip GYH. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103 (4) 683-685
• 43 Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165 (13) 1527-1532
• 44 Fisher CM. Cerebral miliary aneurysms in hypertension. Am J Pathol 1972; 66 (2) 313-330
• 45 Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18 (2) 311-324
• 46 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36 (7) 1588-1593
• 47 Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl) 257S-298S
• 48 Hart RG. What causes intracerebral hemorrhage during warfarin therapy?. Neurology 2000; 55 (7) 907-908
• 49 Dequatre-Ponchelle N, Hénon H, Pasquini M , et al. Vitamin K antagonists-associated cerebral hemorrhages: what are their characteristics?. Stroke 2013; 44 (2) 350-355
• 50 Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59 (2) 193-197
• 51 Hylek EM, Go AS, Chang Y , et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349 (11) 1019-1026
• 52 Lee GH, Kwon SU, Kang DW. Warfarin-induced intracerebral hemorrhage associated with microbleeds. J Clin Neurol 2008; 4 (3) 131-133
• 53 Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94 (3) 537-543
• 54 Holbrook AM, Pereira JA, Labiris R , et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165 (10) 1095-1106
• 55 Granger CB, Alexander JH, McMurray JJV , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
• 56 Patel MR, Mahaffey KW, Garg J , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
• 57 Fazekas F, Kleinert R, Roob G , et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999; 20 (4) 637-642
• 58 Guo LF, Wang G, Zhu XY, Liu C, Cui L. Comparison of ESWAN, SWI-SPGR, and 2D T2*-Weighted GRE sequence for depicting cerebral microbleeds. Clin Neuroradiol 2013; 23 (2) 121-127
• 59 Tanaka A, Ueno Y, Nakayama Y, Takano K, Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke 1999; 30 (8) 1637-1642
• 60 Naka H, Nomura E, Takahashi T , et al. Combinations of the presence or absence of cerebral microbleeds and advanced white matter hyperintensity as predictors of subsequent stroke types. AJNR Am J Neuroradiol 2006; 27 (4) 830-835
• 61 Roob G, Schmidt R, Kapeller P, Lechner A, Hartung HP, Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999; 52 (5) 991-994
• 62 Lovelock CE, Cordonnier C, Naka H , et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010; 41 (6) 1222-1228
• 63 Fan YH, Zhang L, Lam WW, Mok VC, Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke 2003; 34 (10) 2459-2462
• 64 Lee SH, Ryu WS, Roh JK. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 2009; 72 (2) 171-176
• 65 Biffi A, Sonni A, Anderson CD , et al; International Stroke Genetics Consortium. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68 (6) 934-943
• 66 Woo D, Sauerbeck LR, Kissela BM , et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002; 33 (5) 1190-1195
• 67 Biffi A, Anderson CD, Jagiella JM , et al; International Stroke Genetics Consortium. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011; 10 (8) 702-709
• 68 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (5) 1093-1100
• 69 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33 (12) 1500-1510
• 70 Brott T, Broderick J, Kothari R , et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28 (1) 1-5
• 71 Davis SM, Broderick J, Hennerici M , et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66 (8) 1175-1181
• 72 Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003; 89 (2) 278-283
• 73 Huttner HB, Schellinger PD, Hartmann M , et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37 (6) 1465-1470
• 74 Biffi A, Battey TW, Ayres AM , et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011; 77 (20) 1840-1846
• 75 Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol 2005; 4 (10) 662-672
• 76 Greenberg CH, Frosch MP, Goldstein JN, Rosand J, Greenberg SM. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS ONE 2012; 7 (10) e48458
• 77 Demchuk AM, Dowlatshahi D, Rodriguez-Luna D , et al; PREDICT/Sunnybrook ICH CTA study group. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012; 11 (4) 307-314
• 78 Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol 2006; 5 (1) 53-63
• 79 Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 2011; 42 (6) 1781-1786
• 80 Xi G, Fewel ME, Hua Y, Thompson Jr BG, Hoff JT, Keep RF. Intracerebral hemorrhage: pathophysiology and therapy. Neurocrit Care 2004; 1 (1) 5-18
• 81 Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27 (5) 894-908
• 82 Ferreira CN, Vieira LM, Dusse LMS , et al. Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses. Blood Coagul Fibrinolysis 2002; 13 (2) 129-134
• 83 Rizos T, Jenetzky E, Herweh C , et al. Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol 2010; 67 (6) 788-793
• 84 Rizos T, Jenetzky E, Herweh C, Unterberg A, Hacke W, Veltkamp R. Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage. Neurocrit Care 2010; 13 (3) 321-325
• 85 Freeman WD, Brott TG, Barrett KM , et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004; 79 (12) 1495-1500
• 86 Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev 1998; 12 (1) 35-44
• 87 Ansell J, Hirsh J, Hylek E , et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S
• 88 Baglin TP, Keeling DM, Watson HG. British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition–2005 update. Br J Haematol 2006; 132 (3) 277-285
• 89 Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45 (5) 1113-1118 , discussion 1118–1119
• 90 Freeman WD, Aguilar MI. Management of warfarin-related intracerebral hemorrhage. Expert Rev Neurother 2008; 8 (2) 271-290
• 91 Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?. J Thromb Haemost 2006; 4 (5) 963-966
• 92 Foerch C, Arai K, Van Cott EM, van Leyen K, Lo EH. Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage. J Cereb Blood Flow Metab 2009; 29 (5) 1015-1021
• 93 Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke 2011; 42 (1) 191-195
• 94 Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998; 74 (Suppl. 01) 219-223
• 95 Hanley JP. Warfarin reversal. J Clin Pathol 2004; 57 (11) 1132-1139
• 96 Bianco C. Choice of human plasma preparations for transfusion. Transfus Med Rev 1999; 13 (2) 84-88
• 97 Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83 (2) 137-143
• 98 Junagade P, Grace R, Gover P. Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology 2007; 12 (5) 439-440
• 99 Köhler M, Hellstern P, Lechler E, Uberfuhr P, Müller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 1998; 80 (3) 399-402
• 100 Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009; 23 (1) 1-9
• 101 Steiner T, Freiberger A, Griebe M , et al. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages–the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex. Int J Stroke 2011; 6 (3) 271-277
• 102 Broderick J, Connolly S, Feldmann E , et al; American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38 (6) 2001-2023
• 103 Mayer SA, Brun NC, Begtrup K , et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (8) 777-785
• 104 Mayer SA, Brun NC, Begtrup K , et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-2137
• 105 Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9 (8) 741-748
• 106 Sørensen B, Johansen P, Nielsen GL, Sørensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14 (5) 469-477
• 107 Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2 (3) 263-267
• 108 Zhou W, Schwarting S, Illanes S , et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42 (12) 3594-3599
• 109 Zhou W, Zorn M, Nawroth P , et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44 (3) 771-778
• 110 Lauer A, Cianchetti FA, Van Cott EM , et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation 2011; 124 (15) 1654-1662
• 111 Steiner T, Bösel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke 2010; 41 (2) 402-409
• 112 Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344 (19) 1450-1460
• 113 Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012; 11 (12) 1066-1081
• 114 Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl. 01) S119-S126
• 115 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
• 116 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
• 117 Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke 2011; 42 (12) 3661-3662
• 118 Veltkamp R, Jüttler E, Pfefferkorn T, Purrucker J, Ringleb P. [Current registry studies of acute ischemic stroke]. Nervenarzt 2012; 83 (10) 1270-1274
• 119 Khadzhynov D, Wagner F, Formella S , et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109 (4) 596-605
• 120 Kaatz S, Kouides PA, Garcia DA , et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl. 01) S141-S145
• 121 Vigué B, Ract C, Tremey B , et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33 (4) 721-725
• 122 Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke 2009; 40 (6) 2068-2072
• 123 Broderick J, Connolly S, Feldmann E , et al; American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38 (6) 2001-2023
• 124 Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34 (7) 1710-1716
• 125 Holmes DR, Reddy VY, Turi ZG , et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374 (9689) 534-542